European Journal of Cancer
Volume 45, Issue 18 , Pages 3149-3155 , December 2009

The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen

  • Evangelos Chandanos

      Affiliations

    • Corresponding Author InformationCorresponding author: Address: Norra Stationsgatan 67, II Karolinska Institutet, SE-171 76 Stockholm, Sweden. Tel.: +46 8 517709 57; fax: +46 8 33 15 87.
    • ,
  • Jesper Lagergren

Received 30 May 2009 ,Revised 24 August 2009 ,Accepted 2 September 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  2. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2004; 2006.
  3. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190(5):562–72 [discussion 572–3].
  4. Turnbull AD, Goodner JT. Primary adenocarcinoma of the esophagus. Cancer. 1968;22(5):915–918
  5. Bosch A, Frias Z, Caldwell WL. Adenocarcinoma of the esophagus. Cancer. 1979;43(4):1557–1561
  6. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–1289
  7. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104(2):510–513
  8. Dolan K, Sutton R, Walker SJ, et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer. 1999;80(5–6):834–842
  9. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–1187
  10. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer. 1993;54(3):402–407
  11. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1992;1(3):265–269
  12. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer. 2002;102(4):422–427
  13. Tuyns AJ. Oesophageal cancer in France and Switzerland: recent time trends. Eur J Cancer Prev. 1992;1(3):275–278
  14. Liabeuf A, Faivre J. Time trends in oesophageal cancer incidence in Cote d’Or (France), 1976–93. Eur J Cancer Prev. 1997;6(1):24–30
  15. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway 1958–1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer. 1997;71(3):340–344
  16. Levi F, Randimbison R, La Vecchia C. Esophageal and gastric carcinoma in Vaud, Switzerland, 1976–1994. Int J Cancer. 1998;75(1):160–161
  17. McKinney A, Sharp L, Macfarlane GJ, Muir CS. Oesophageal and gastric cancer in Scotland 1960–90. Br J Cancer. 1995;71(2):411–415
  18. Moller H. Incidence of cancer of oesophagus, cardia and stomach in Denmark. Eur J Cancer Prev. 1992;1(2):159–164
  19. Spechler SJ, Goyal RK. Barrett’s esophagus. New Engl J Med. 1986;315(6):362–371
  20. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl J Med. 1999;340(11):825–831
  21. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003;98(5):940–948
  22. Ye W, Chow WH, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121(6):1286–1293
  23. Abnet CC, Freedman ND, Hollenbeck AR, et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer. 2008;44(3):465–471
  24. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Contr. 2001;12(8):721–732
  25. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Contr. 2005;16(3):285–294
  26. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130(11):883–890
  27. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90(2):150–155
  28. Engeland A, Tretli S, Bjorge T. Height and body mass index in relation to esophageal cancer; 23-year follow-up of two million Norwegian men and women. Cancer Causes Contr. 2004;15(8):837–843
  29. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 1995;4(2):85–92
  30. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer. 2000;85(3):340–346
  31. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1997;89(17):1277–1284
  32. Weston AP, Badr AS, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett’s esophagus, Barrett’s dysplasia, and Barrett’s adenocarcinoma. Am J Gastroenterol. 2000;95(2):387–394
  33. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58(4):588–590
  34. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004;96(5):388–396
  35. Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003;103(6):815–821
  36. Bahmanyar S, Zendehdel K, Nyren O, Ye W. Risk of oesophageal cancer by histology among patients hospitalised for gastroduodenal ulcers. Gut. 2007;56(4):464–468
  37. Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr. 2002;132(11 Suppl):3467S–3470S
  38. Jansson C, Johansson AL, Nyren O, Lagergren J. Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. Cancer Epidemiol Biomark Prev. 2005;14(7):1754–1761
  39. Brown LM, Hoover R, Silverman D, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol. 2001;153(2):114–122
  40. Terry P, Lagergren J, Hansen H, Wolk A, Nyren O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev. 2001;10(4):365–369
  41. Garidou A, Tzonou A, Lipworth L, et al. Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer. 1996;68(3):295–299
  42. Terry P, Lagergren J, Wolk A, Nyren O. Drinking hot beverages is not associated with risk of oesophageal cancers in a Western population. Br J Cancer. 2001;84(1):120–121
  43. Sandler RS, Nyren O, Ekbom A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA 1995;274(17):1359–62.
  44. Csikos M, Horvath O, Petri A, Petri I, Imre J. Late malignant transformation of chronic corrosive oesophageal strictures. Langenbecks Arch Chir. 1985;365(4):231–238
  45. Larsson LG, Sandstrom A, Westling P. Relationship of Plummer-Vinson disease to cancer of the upper alimentary tract in Sweden. Cancer Res 1975;35(11 Pt 2):3308–16.
  46. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 2001;30(6):1415–1425
  47. MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer. 2006;118(10):2628–2631
  48. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology 2007;133(1):34–41 [quiz 311].
  49. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17(2):352–358
  50. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett’s esophagus. Gastroenterology. 2007;133(2):403–411
  51. Santosa S, Jensen MD. Why are we shaped differently, and why does it matter?. Am J Physiol Endocrinol Metab. 2008;295(3):E531–E535
  52. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991;40(12):1323–1326
  53. Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab. 1997;82(2):414–417
  54. Pedersen SB, Bruun JM, Hube F, et al. Demonstration of estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell differentiation and fat depot localization. Mol Cell Endocrinol. 2001;182(1):27–37
  55. Dieudonne MN, Leneveu MC, Giudicelli Y, Pecquery R. Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. Am J Physiol Cell Physiol. 2004;286(3):C655–C661
  56. Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut. 2009;58(2):182–188
  57. Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162(11):1050–1061
  58. van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Age and sex distribution of the incidence of Barrett’s esophagus found in a Dutch primary care population. Am J Gastroenterol. 2005;100(11):2599–2600
  59. van Blankenstein M, Looman CW, Johnston BJ, Caygill CP. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am J Gastroenterol. 2005;100(3):568–576
  60. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207(1):12–22
  61. Kendall BJ, Macdonald GA, Hayward NK, et al. Leptin and the risk of Barrett’s oesophagus. Gut. 2008;57(4):448–454
  62. Williams LB, Fawcett RL, Waechter AS, et al. Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab. 2000;85(8):2678–2684
  63. Lagergren J, Nyren O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomark Prev. 1998;7(10):913–915
  64. Khushalani N. Cancer of the esophagus and stomach. Mayo Clin Proc. 2008;83(6):712–722
  65. van Blankenstein M, Looman CW, Hop WC, Bytzer P. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett’s esophagus makes a difference. Am J Gastroenterol. 2005;100(4):766–774
  66. Kobayashi K. Effect of sex hormone on the experimental induction of esophageal cancer. Nippon Geka Gakkai Zasshi. 1985;86(3):280–289
  67. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93(12):5925–5930
  68. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986;231(4742):1150–1154
  69. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986;320(6058):134–139
  70. Tiffin N, Suvarna SK, Trudgill NJ, Riley SA. Sex hormone receptor immunohistochemistry staining in Barrett’s oesophagus and adenocarcinoma. Histopathology. 2003;42(1):95–96
  71. Akgun H, Lechago J, Younes M. Estrogen receptor-beta is expressed in Barrett’s metaplasia and associated adenocarcinoma of the esophagus. Anticancer Res. 2002;22(3):1459–1461
  72. Liu L, Chirala M, Younes M. Expression of estrogen receptor-beta isoforms in Barrett’s metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res 2004;24(5A):2919–24.
  73. Kalayarasan R, Ananthakrishnan N, Kate V, Basu D. Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus. 2008;21(4):298–303
  74. Utsumi Y, Nakamura T, Nagasue N, Kubota H, Morikawa S. Role of estrogen receptors in the growth of human esophageal carcinoma. Cancer. 1989;64(1):88–93
  75. Nozoe T, Oyama T, Takenoyama M, et al. Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2007;13(14):4046–4050
  76. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998;247(1):75–78
  77. Ogawa S, Inoue S, Watanabe T, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucl Acids Res. 1998;26(15):3505–3512
  78. Utsumi Y, Nakamura T, Nagasue N, et al. Effect of 17 beta-estradiol on the growth of an estrogen receptor-positive human esophageal carcinoma cell line. Cancer. 1991;67(9):2284–2289
  79. Joubert A, Marais S. In vitro effects of 2-methoxyestradiol on cell morphology and Cdc2 kinase activity in SNO oesophageal carcinoma cells. Cell Biochem Funct. 2007;25(3):357–362
  80. Joubert A, Maritz C, Joubert F. Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. Biomed Res. 2005;26(3):131–134
  81. Morani A, Warner M, Gustafsson JA. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med 2008.
  82. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001;61(14):5331–5335
  83. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61(6):2537–2541
  84. Chandanos E, Rubio C, Lindblad M, Jia C, Tsolakis A, Warner M, et al. Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer. 2008;11(3):168–174
  85. Wang M, Pan JY, Song GR, et al. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 2007;33(2):195–201
  86. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39(9):1251–1258
  87. Uchikado Y, Natsugoe S, Okumura H, et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11(3):1174–1180
  88. Wada-Hiraike O, Hiraike H, Okinaga H, et al. Role of estrogen receptor beta in uterine stroma and epithelium: insights from estrogen receptor beta−/− mice. Proc Natl Acad Sci USA. 2006;103(48):18350–18355
  89. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. New Engl J Med. 2004;350(10):991–1004
  90. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872–881
  91. Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44(16):2397–2403
  92. Palli D, Cipriani F, Decarli A, et al. Reproductive history and gastric cancer among post-menopausal women. Int J Cancer. 1994;56(6):812–815
  93. La Vecchia C, D’Avanzo B, Franceschi S. Menstrual and reproductive factors and gastric-cancer risk in women. Int J Cancer. 1994;59(6):761–764
  94. Kaneko S, Tamakoshi A, Ohno Y, Mizoue T, Yoshimura T. Menstrual and reproductive factors and the mortality risk of gastric cancer in Japanese menopausal females. Cancer Causes Contr. 2003;14(1):53–59
  95. Lindblad M, Ye W, Rubio C, Lagergren J. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomark Prev. 2004;13(12):2203–2207
  96. Frise S, Kreiger N, Gallinger S, Tomlinson G, Cotterchio M. Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the Canadian national enhanced cancer surveillance system. Ann Epidemiol. 2006;16(12):908–916
  97. Freedman ND, Chow WH, Gao YT, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut. 2007;
  98. Furukawa H, Iwanaga T, Koyama H, Taniguchi H. Effect of sex hormones on the experimental induction of cancer in rat stomach – a preliminary study. Digestion. 1982;23(3):151–155
  99. Furukawa H, Iwanaga T, Koyama H, Taniguchi H. Effect of sex hormones on carcinogenesis in the stomachs of rats. Cancer Res. 1982;42(12):5181–5182
  100. Campbell-Thompson M, Lauwers GY, Reyher KK, Cromwell J, Shiverick KT. 17Beta-estradiol modulates gastroduodenal preneoplastic alterations in rats exposed to the carcinogen N-methyl-N′-nitro-nitrosoguanidine. Endocrinology. 1999;140(10):4886–4894
  101. Furukawa H, Iwanaga T, Hiratsuka M, et al. Suppressive effect of sex hormones on spreading of stomach cancer. Gan To Kagaku Ryoho. 1989;16(12):3691–3695
  102. Matsuoka H, Sugimachi K, Ueo H. Sex hormone response of a newly established squamous cell line derived from clinical esophageal carcinoma. Cancer Res. 1987;47(15):4134–4140
  103. Ueo H, Matsuoka H, Sugimachi K. Inhibitory effects of estrogen on the growth of a human esophageal carcinoma cell line. Cancer Res. 1990;50(22):7212–7215
  104. Yamashita Y, Hirai T, Mukaida H, et al. Detection of androgen receptors in human esophageal cancer. Jpn J Surg. 1989;19(2):195–202
  105. Shirai T, Tsuda H, Ogiso T, Hirose M, Ito N. Organ specific modifying potential of ethinyl estradiol on carcinogenesis initiated with different carcinogens. Carcinogenesis. 1987;8(1):115–119
  106. Miller AB, Barclay TH, Choi NW, et al. A study of cancer, parity and age at first pregnancy. J Chronic Dis. 1980;33(10):595–605
  107. La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. Int J Cancer. 1993;53(2):215–219
  108. Lagergren J, Jansson C. Sex hormones and oesophageal adenocarcinoma: influence of childbearing?. Br J Cancer. 2005;93(8):859–861
  109. Lindblad M, Garcia Rodriguez LA, Chandanos E, Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006;94(1):136–141
  110. Gallus S, Bosetti C, Franceschi S, et al. Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors. Br J Cancer. 2001;85(3):341–345
  111. Midgette AS, Baron JA. Cigarette smoking and the risk of natural menopause. Epidemiology. 1990;1(6):474–480
  112. Cheng KK, Sharp L, McKinney PA, et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer. 2000;83(1):127–132
  113. Reeves GK, Pirie K, Beral V. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134
  114. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. New Engl J Med. 2002;346(5):340–352
  115. Osborne CK. Tamoxifen in the treatment of breast cancer. New Engl J Med. 1998;339(22):1609–1618
  116. Chandanos E, Lindblad M, Jia C, et al. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer. 2006;95(1):118–122
  117. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991;83(14):1013–1017
  118. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–537
  119. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87(9):645–51.
  120. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 1996;88(12):832–834
  121. Matsuyama Y, Tominaga T, Nomura Y, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol. 2000;11(12):1537–1543
  122. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett’s oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39(12):1175–9.

PII: S0959-8049(09)00673-X

doi: 10.1016/j.ejca.2009.09.001

European Journal of Cancer
Volume 45, Issue 18 , Pages 3149-3155 , December 2009

Article Tools